Similar to CD93, CLEC14A was described as a key gene in a proposed ‘tumour angiogenesis signature’ determined by meta‐analysis of over 1000 tumour samples including breast, renal and head and neck cancers 154. This evidence concerns the gene CD93 and head and neck cancer.